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Abstract
CD317/tetherin (aka BST2 or HM1.24 antigen) is an interferon inducible membrane protein present in regions of the
lipid bilayer enriched in sphingolipids and cholesterol (often termed lipid rafts). It has been implicated in an eclectic
mix of cellular processes including, most notably, the retention of fully formed viral particles at the surface of cells
infected with HIV and other enveloped viruses. Expression of the HIV viral accessory protein Vpu has been shown to
lead to intracellular sequestration and degradation of tetherin, thereby counteracting the inhibition of viral release.
There is evidence that tetherin interacts directly with Vpu, but it remains unclear where in the cell this interaction
occurs or if Vpu expression affects the lipid raft localisation of tetherin. We have addressed these points using
biochemical and cell imaging approaches focused on endogenous rather than ectopically over-expressed tetherin.
We find i) no evidence for an interaction between Vpu and endogenous tetherin at the cell surface, ii) the vast
majority of endogenous tetherin that is at the cell surface in control cells is in lipid rafts, iii) internalised tetherin is
present in non-raft fractions, iv) expression of Vpu in cells expressing endogenous tetherin leads to the loss of
tetherin from lipid rafts, v) internalised tetherin enters early endosomes, and late endosomes, in both control cells and
cells expressing Vpu, but the proportion of tetherin molecules destined for degradation rather than recycling is
increased in cells expressing Vpu vi) lysosomes are the primary site for degradation of endogenous tetherin in cells
expressing Vpu. Our studies underlie the importance of studying endogenous tetherin and let us propose a model in
which Vpu intercepts newly internalised tetherin and diverts it for lysosomal destruction rather than recycling to the
cell surface.
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Introduction
CD317/tetherin (aka BST2 or HM1.24 antigen [1,2]) is an
interferon inducible membrane protein [3] that causes retention
of fully formed viral particles at the surface of HIV infected cells
[4,5]. In fact it has been shown to restrict the release of a range
of enveloped viruses from infected cells (reviewed in [6]) as
well as having been implicated in an eclectic mix of cellular
processes (summarized in [7]).
Tetherin possesses both a conventional transmembrane
(TM) domain and a glycosylphosphatidylinositol (GPI) anchor
[8]. The presence of a GPI anchor has been shown by both
biochemical means [8] and by a targeted proteomics approach
[9] and is consistent with studies in a CHO cell line deficient in
the enzyme required for the addition of GPI anchors [10];
however a recent report suggests that the C-terminal
hydrophobic region of tetherin serves as a second TM domain
rather than as a signal for the addition of a GPI anchor [11].
Tetherin resides – at least at the cell surface – in lipid rafts
(membrane microdomains in which there is a ‘preferential
association between sphingolipids, sterols, and specific
proteins’ [12,13]) with the TM domain apparently lying outside
the raft (or at the interface of the raft and non-raft domains) and
with the raft localisation being dependent upon the GPI anchor
[8,14]. The extracellular domain of tetherin has been shown to
form a disulphide bonded parallel coiled coil, thereby
generating a dimer with two adjacent TM domains and two
adjacent GPI anchors separated by ~17nm [15,16,17,18]. It
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has been suggested that the structure of tetherin plays a role in
the mechanism by which it restricts the release of newly formed
viral particles from infected cells [15,16,17,18].
Several enveloped viruses have evolved specific
mechanisms to counteract the restriction imposed by tetherin.
This generally involves expression of a viral protein which
interacts with tetherin (e.g. Ebola virus GP) [19,20], in some
cases leading to the degradation of tetherin (e.g. the K5
ubiquitin ligase of Kaposi’s sarcoma-associated herpesvirus)
[21]. In the case of HIV-1, it is the viral accessory protein Vpu
that has been shown to antagonise tetherin [5,22,23,24]. Vpu is
a member of a family of viral proteins, termed viroporins, that
oligomerise to form channels in membranes [25]. Vpu has a
single TM domain, but oligomerises to form a pentameric ion
channel in the membrane [26,27]. The precise mechanism by
which Vpu antagonizes tetherin remains unclear, as there are
conflicting data in the literature (reviewed in [6,24,28]).
Tetherin and Vpu have been shown to interact, with this
interaction being dependent upon residues within the TM
domains of the two proteins, principally residues located at the
extracellular ends of their TM domains [23,29,30,31,32,33,34].
However the stoichiometry and organisation of this interaction
has not been characterized, i.e. does each monomer in a Vpu
tetramer/pentamer interact with a tetherin dimer or is there
some other arrangement? What is known is that mutations
which abrogate the interaction between tetherin and Vpu
restore the capacity of tetherin to restrict viral release
(reviewed in [28]). The interaction between tetherin and Vpu
leads to the degradation of tetherin, with some dispute as to
whether this is primarily via a lysosomal or proteasomal
mediated pathway (reviewed in [6,24,28]) but with the more
recent and more compelling evidence being in favour of
lysosomal degradation [35,36,37]. However the degradation of
tetherin does not appear to be an absolute requirement for
overcoming its restriction of viral release [38,39], with several
reports of Vpu-mediated sequestration of tetherin in the trans
Golgi network (TGN) being sufficient [36,37,40,41] and at least
one report that the primary antagonistic effect of Vpu on
tetherin is upon newly synthesised tetherin as the latter is being
transported to the cell surface [42]. It is of note though, given
the lipid raft localisation of tetherin, that lipid raft association of
Vpu has been shown to correlate with enhanced virus release
[43]. Indeed, Dube et al comment ‘It will be important to
determine whether Vpu targets a pool of Tetherin located in
specific microdomains of the plasma membrane’ [6].
There have been reports of the interaction between tetherin
and Vpu occurring at various cellular locations, including the
endoplasmic reticulum (ER) [42], TGN [40] and the cell surface
[44,45]. However, the latter studies provide no direct evidence
for the tetherin:Vpu interaction occurring at the cell surface.
Interpretation of data from studies on the effects of Vpu on
tetherin have been complicated by the fact that many have
monitored epitope-tagged tetherin expressed in cells that do
not express endogenous tetherin (HEK293T cells are most
commonly used). Notably, the different forms of tetherin
(immature, fully glycosylated etc.) are present in different
proportions in transiently transfected cells compared to the
endogenous protein (e.g. [24]). Even minor changes to the
tetherin sequence have been shown to compromise the
efficiency with which it restricts virion release (reviewed in [46]),
making it difficult to predict the effect of an epitope tag (such as
is commonly used when recombinant tetherin is expressed in
cells) upon the Vpu-mediated fate of tetherin. We therefore set
out to investigate the effects of Vpu expression on the
localisation and fate of endogenous tetherin in HeLa cells.
Results
Do Vpu and tetherin interact at the cell surface?
We initially chose to confirm that we could co-
immunoprecipitate endogenous tetherin with Vpu. HeLa cells
(which express endogenous tetherin) were transiently
transfected to express GFP-tagged Vpu and, 24 hours post
transfection, cells were lysed and processed for
immunoprecipitation using the GFP-trap monoclonal antibody
(see Methods). As anticipated, tetherin was efficiently co-
immunoprecipitated with Vpu (Figure 1A).
It has been suggested, but not directly demonstrated, that
the Vpu-tetherin interaction can occur at the cell surface
[44,45]. We tested this directly by using a cell surface
biotinylation and co-immunoprecipitation approach. HeLa cells
were transiently transfected to express GFP-tagged Vpu and,
24hrs later, labeled with a membrane impermeant biotin
reagent at 4°C (see Methods). This procedure labels only the
extracellular domains of proteins (on lysine residues) exposed
at the cell surface and the low temperature will prevent their
internalisation. Excess biotin was then washed away (at 4°C)
and aliquots of cells either immediately processed for
immunoprecipitation, or transferred to 37°C for various periods
of time before being processed for immunoprecipitation, using
the GFP-trap monoclonal antibody. Endocytosis of cell surface
proteins occurs following the increase in temperature to 37°C,
and therefore allows one to follow the intermolecular
interactions of biotinylated proteins that have been at the cell
surface following their internalisation. Immunoprecipitated
material was then separated into that which bound to
strepatavidin-agarose (corresponding to the biotinylated
proteins) and that which did not (i.e. non-biotinylated proteins).
The different fractions were then subjected to SDS-PAGE and
immunoblot analysis using an anti-tetherin antibody as primary
antibody (see flow diagram in Figure 1B). No biotinylated
tetherin could be detected in the GFP-trap immunoprecipitate
of lysate from cells that had been kept at 4°C (Figure 1C lane
2), indicating a lack of detectable interaction between tetherin
and Vpu at the cell surface. However, biotinylated tetherin
could be detected in the GFP-trap immunoprecipitate of lysate
from cells that had been incubated at 37°C for 10 min following
labeling at 4°C (Figure 1C lane 5). This suggests that either a)
tetherin and Vpu do interact at the cell surface, but that their
internalisation occurs as soon as they have interacted, or b) the
interaction between Vpu and tetherin occurs very early in the
endocytic pathway. It is of note that it is a high molecular
weight (~75kDa) form of biotinylated tetherin that co-
immunoprecipitates with Vpu-GFP following internalisation of
the biotinylated tetherin from the cell surface. This potentially
represents an SDS-resistant dimer of tetherin and implies
Vpu Leads to Loss of Tetherin from Lipid Rafts
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Figure 1.  Tetherin interacts with Vpu in whole cells, but does not do so at the cell surface.  A. Immunoblot of tetherin in
whole cell lysates from HeLa cells transfected to express Vpu-GFP (left panel) or GFP alone (right panel) and incubated in the
presence of proteosomal inhibitors (PI) or lysosomal inhibitors (LI) as indicated. These inhibitors were included in order to block any
Vpu-mediated degradation of tetherin, thereby ensuring sufficient tetherin remains for detection by immunoblot. Tetherin was
detected in whole cell lysates (10% of input; GFP-TRP – lanes) and in co-immunoprecipitates with Vpu-GFP, but not in co-
immunoprecipitates with GFP (GFP-TRP + lanes).
B. Flow diagram to illustrate procedure for isolation and identification of any biotinylated tetherin that interacts with Vpu, either at the
cell surface (biotinylation at 4°C) or in an endosomal compartment following internalization from the cell surface (biotinylation at 4°C
followed by a 10 min chase at 37°C).
C. HeLa cells were processed as outlined in B (above) and samples were processed for immunoblot analysis using an antibody to
tetherin. Tetherin is detected in the whole cell lysate (10% of input) from cells labeled with biotin at 4°C (0 min) (lane 1) and from
cells labeled with biotin at 4°C followed by a 10 min chase at 37°C (10 min) (lane 4). Tetherin is not detected in the GFP Trap and
streptavidin pull-down from cells labeled with biotin at 4°C (0 min) (lane 2), indicating that cell surface tetherin does not interact with
Vpu. Multiple cell surface proteins were biotinylated by the procedure used, as shown by their detection in the whole cell lysate
using streptavidin HRP (lane 3). Tetherin is detected in the GFP Trap and streptavidin pull-down from cells labeled with biotin at 4°C
then subjected to a 10 min chase at 37°C (10 min) (lane 5), indicating that tetherin does interact with Vpu upon internalisation.
Tetherin can be detected in material isolated from the 10 min chase lysate by streptavidin-coated beads (lane 6).
doi: 10.1371/journal.pone.0075680.g001
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preferential interaction of this form of tetherin with Vpu-GFP.
Not all of the biotinylated tetherin in lysate from cells that had
been incubated at 37°C for 10 min following labeling at 4°C is
present as an SDS-resistant dimer, as shown by the fact that a
lower molecular weight form of tetherin can be isolated from
this lysate using streptavidin beads (Figure 1C lane 6)
Does expression of Vpu affect the distribution of
tetherin at the cell surface?
We next asked whether expression of Vpu affects the
distribution of endogenous tetherin in the plasma membrane.
First, we tested the association of tetherin with lipid rafts
through membrane flotation assays. Untransfected HeLa cells,
or cells transfected to express an HA-tagged tetherin construct,
were lysed in ice-cold 1% Triton X-100 and separated on
sucrose density gradients before immunoblotting with
antibodies to either tetherin (for the endogenous protein) or the
HA tag (to detect the transfected protein) respectively. Some,
but not all of the endogenous tetherin is present in the low
density fractions representing lipid rafts (Figure 2, second
panel), as we have shown previously [7,8]. This is consistent
with the current view of the plasticity of membrane
microdomains at the cell surface [12,13]. However, when
recombinant tetherin is expressed in HeLa cells a significant
proportion is not present in lipid rafts, implying that the rafts
have become saturated for tetherin [7] and (Figure 2 upper
panel). In contrast, when recombinant tetherin is expressed in
HEK293T cells (chosen because they do not express
detectable levels of endogenous tetherin and are frequently
used as a background in which to express recombinant tetherin
constructs), the majority of the tetherin molecules are present
in lipid rafts (Figure 2B), a finding that was not altered by the
co-expression of Vpu (Figure 2B lower panels). These
observations of differential behaviour between endogenous
and recombinant tetherin re-enforced our rationale for
investigating the relationship between endogenous tetherin and
Vpu.
To test the effect of Vpu on the raft-association of
endogenous tetherin, control HeLa cells and HeLa cells that
had been transfected to transiently express Vpu-GFP were
lysed in ice cold Triton X-100 and separated on sucrose
density gradients. Fractions from the gradients were then
subjected to SDS-PAGE and immunoblot analysis. A
proportion of mature tetherin molecules is present in the raft
fractions (1-4) in lysate from control cells, but a substantially
lower proportion is raft localised in lysate from cells expressing
Vpu (Figure 3A panels 1+2). When the proportion of
endogenous tetherin present in raft vs. non-raft fractions was
quantified (by densitometry) 36 +/- 4% of tetherin molecules
were detected in raft fractions in control cells, while expression
of Vpu-GFP lowered this to only 14 +/- 3% (Figure 3B, n = 5).
Similar results were obtained using cells expressing untagged
Vpu (data not shown). In contrast, when the effect of Vpu was
tested on recombinant tetherin expressed in HEK293T cells,
co-expression of Vpu did not lead to redistribution of
recombinant tetherin to non-raft fractions (Figure 2B). The
distribution of Vpu-GFP across the sucrose gradient was also
analysed by immunoblotting; in both cell types it has a broad
distribution across the gradient (Figure 2B, bottom panel,
Figure 3A panel 3), indicating that it is present in a range of
membrane environments, both raft and non-raft. The effect of
Vpu-GFP expression on the raft vs. non-raft distribution of
endogenous tetherin is not a generic effect of viroporin
expression, as expression of the Influenza virus M2 protein
(another viroporin) had no effect on the raft localisation of
tetherin (Figure 3A panels 4+5).
Thus, expression of Vpu correlates with a redistribution of
endogenous tetherin from raft to non-raft membrane
environments, but this does not necessarily mean that a direct
interaction between the two proteins is the mechanism by
which tetherin is removed from lipid rafts.
What is the sub-cellular location of tetherin that is in
lipid rafts?
The preceding result led us to question whether the tetherin
that is in lipid rafts in control cells is at the cell surface or in
intracellular compartments (N.B. tetherin constitutively cycles
between the cell surface and an intracellular pool [8,47]). HeLa
cells were again labeled with a membrane impermeant biotin
reagent at 4°C prior to either immediate lysis in ice cold 1%
Triton X-100, or incubation for 10 min at 37°C before lysis in ice
cold 1% Triton X-100. Lysates were then separated on sucrose
density gradients as before. Fractions 1-4 were pooled as raft
fractions, and 5-8 and 9-12 as two separate non-raft fractions.
Lysates were then incubated with streptavidin-agarose beads
to separate biotinylated (either cell surface in the case of
immediate lysis after biotinylation at 4°C, or internalised after a
10 min chase at 37°C, proteins) from non-biotinylated material.
As expected the total population of tetherin molecules is ~ 35%
raft localized (Figure 4A ‘Total’), however the tetherin that is at
the cell surface (i.e. the biotinylated tetherin at 0 min uptake at
37°C) is almost exclusively raft localized (Figure 4A ‘Plasma
Membrane’). After 10 min uptake at 37°C a significant
proportion of biotinylated tetherin is present in non-raft fractions
(Figure 4A ‘Internalised’). Since it has been shown that not all
tetherin molecules will have been internalised in 10 min [36,40],
it is probable that the fraction of tetherin that remains raft
associated following 10 min incubation at 37°C is still at the cell
surface. Thus, these data are consistent with tetherin exiting
lipid rafts upon, or immediately prior to, internalisation.
Expression of Vpu has no significant effect on this distribution
pattern (Figure 4B), implying that the preferential redistribution
of the total population of tetherin molecules to non-raft fractions
upon expression of Vpu in cells (as observed in Figure 3) is in
fact a consequence of a reduction in the levels of tetherin at the
cell surface in the presence of Vpu (as has been described
previously, e.g. [5]) rather than a Vpu-mediated lateral
movement of tetherin out of lipid rafts in the plane of the lipid
bilayer of the plasma membrane. In contrast to the situation
with tetherin, most Transferrin receptor molecules are in the
non-raft fractions and most Flotillin-2 molecules are in the raft
fractions, under all conditions assayed (Figure 4A lower
panels).
It is of note that the internalised tetherin is detected as bands
corresponding to both monomeric and dimeric forms of tetherin
(Figure 4A and B ‘Internalised’). This is under reducing
Vpu Leads to Loss of Tetherin from Lipid Rafts
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Figure 2.  Variation in the degree of localization of tetherin to lipid rafts.  Cells were subjected to extraction in ice-cold Triton
X-100 (1%) prior to separation by sucrose density gradient centrifugation, then analysis of fractions from the gradients by
immunoblot. Fractions 1-4 are considered as the lipid raft fraction, fractions 5-12 as non-raft fractions. A. The top panel shows an
immunoblot, using an antibody to the HA epitope tag on recombinant HA-tagged tetherin expressed in HeLa cells, of fractions from
HeLa cells transfected to express HA-tagged tetherin and shows that the majority of recombinant HA-tagged tetherin is not present
in lipid rafts (i.e. it is in fractions 5-12). The second panel shows an immunoblot, using an antibody to tetherin, of fractions from
HeLa cells and shows that a significant proportion of endogenous tetherin is present in lipid rafts (i.e. in fractions 1-4). B. The first
panel shows an immunoblot, using an antibody to the HA epitope tag on recombinant HA-tagged tetherin expressed in HEK293T
cells (NB HEK293T cells do not express detectable levels of endogenous tetherin), of fractions from HEK293T cells transfected to
express HA-tagged tetherin and shows that the majority of recombinant tetherin is present in lipid rafts (i.e. in fractions 1-4). The
second panel shows the same, but in HEK293T cells that express Vpu-GFP in addition to HA-tagged tetherin: this experiment was
performed in the absence of lysosomal enzyme inhibitors, the blot was exposed longer to ensure detection of tetherin. The bottom
panel shows the distribution of Vpu-GFP expressed in the same cells; it is present in both raft and non-raft fractions.
doi: 10.1371/journal.pone.0075680.g002
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Figure 3.  The effect of expression of Vpu on the lipid raft localisation of endogenous tetherin.  A. HeLa cells were subjected
to extraction in ice-cold Triton X-100 (1%) prior to separation by sucrose density gradient centrifugation, then analysis of fractions
from the gradients by immunoblot. Fractions 1-4 are considered as lipid raft fractions, fractions 5-12 as non-raft fractions. The top
panel shows an immunoblot, using an antibody to tetherin, of fractions from untransfected HeLa cells and confirms that a significant
proportion of endogenous tetherin is present in lipid rafts (i.e. in fractions 1-4). The second panel shows an immunoblot, using an
antibody to tetherin, of fractions from HeLa cells that had been transfected to express Vpu-GFP and shows that the majority of
endogenous tetherin is lost from lipid rafts (i.e. fractions 1-4) in the presence of Vpu-GFP: this experiment was performed in the
absence of lysosomal enzyme inhibitors, the blot was exposed longer to ensure detection of tetherin. Panel 3 shows the distribution
of Vpu-GFP across the sucrose gradient; it has a broad distribution across the gradient, indicating that it is present in a range of
membrane environments, both raft and non-raft. Expression of another viroporin protein (the M2 protein of influenza virus) does not
lead to a redistribution of tetherin from lipid rafts, as shown by the bottom two panels. Panel 4 shows an immunoblot, using an
antibody to tetherin, of fractions from HeLa cells that had been transfected to express M2-GFP and shows that the distribution of
endogenous tetherin is similar to that in non-transfected cells (top panel). The bottom panel shows the distribution of M2-GFP
across the sucrose gradient. B. Graphical representation of the proportions of tetherin molecules in raft vs. non-raft fractions on
control HeLa cell and HeLa cells expressing Vpu-GFP (as indicated, n=5).
doi: 10.1371/journal.pone.0075680.g003
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conditions and in the presence of SDS, and is consistent with
the presence of a tetherin dimer that is resistant to both
reducing conditions and to SDS (as observed to be
preferentially associating with Vpu in Figure 1C). The bands
corresponding to tetherin detected in Figure 4B (i.e. the
internalised tetherin that co-immunoprecipitates with Vpu) are
Figure 4.  Tetherin is in lipid rafts at the cell surface.  A. HeLa cells were labeled with a membrane impermeant biotin reagent at
4°C prior to either immediate lysis in ice cold Triton X-100, or incubation for 10 min at 37°C before lysis in ice cold Triton X-100.
Lysates were then separated on sucrose density gradients and 1 ml fractions were taken. Fractions 1-4 were pooled as raft
fractions, 5-8 and 9-12 as two separate non-raft fractions. Lysates were then incubated with streptavidin-agarose beads to separate
biotinylated (cell surface in the case of immediate lysis after biotinylation at 4°C, or internalised in the case of the 10 min chase at
37°C, proteins) from non-biotinylated proteins. Total, plasma membrane, and internalised fractions were then subjected to
immunoblot analysis using antibodies to endogenous tetherin, Transferrin receptor or Flotillin 2 (the latter two as controls) as
indicated. The total population of tetherin molecules is ~ 35% raft localized (1-4 in Total), however the tetherin that is at the cell
surface (i.e. the biotinylated tetherin at 0 min uptake at 37°C) is almost exclusively raft localized (1-4 in Plasma Membrane). After 10
min uptake at 37°C a significant proportion of biotinylated tetherin is present in non-raft fractions (Figure 4A Internalised). B. As in A,
but using HeLa cells transfected to express Vpu-GFP.
doi: 10.1371/journal.pone.0075680.g004
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also less diffuse than the corresponding bands in Figure 4A
(i.e. the total population of internalised tetherin molecules); this
might indicate that Vpu preferentially interacts with a particular
glycoform (or subset of glycoforms) of the heterogeneously
glycosylated tetherin.
What is the fate of endogenous tetherin in cells
expressing Vpu?
Given that the co-immunoprecipitation data presented in
Figure 1 are consistent with Vpu interacting with tetherin
immediately following the internalisation of tetherin from the cell
surface, we tested if Vpu and endocytosed tetherin could be
detected in a common endocytic compartment. In order to do
this, HeLa cells that had been transiently transfected to
express Vpu-GFP and which had been incubated in the
presence of lysosomal enzyme inhibitors (see Methods) for 24
hours were incubated for 30 min at 4°C in order to halt
endocytosis, and then incubated for a further 15 min at 4°C
with a monoclonal antibody (HM1.24) that recognises the
extracellular domain of tetherin. Cells were then transferred to
37°C for various times and processed for immunofluorescence
analysis (see Methods) using polyclonal antibodies to markers
of early (EEA-1) or late (LAMP-1) endosomes. Some of the
internalised tetherin can be seen to co-localise with both Vpu
and EEA1 after 5 or 10 min at 37°C (Figure 5A and B, white
arrows). However, there is greater evidence of co-localisation
between internalised tetherin and LAMP-1 at both time points
(Figure 5C and D). This co-localisation is greatest in cells that
also express Vpu (quantified in Figure 5E), but it is of note that
there is limited evidence of any co-localisation between Vpu
and LAMP-1 (Figure 5C and D) implying that the presence of
Vpu leads to increased delivery of internalised tetherin to late
endosomes without Vpu itself trafficking to that compartment.
NB the images shown in Figure 5 represent the steady-state
distribution of EEA-1, LAMP-1 and Vpu-GFP, but only the
internalised population of tetherin molecules.
To extend our investigation of the fate of internalised tetherin
in the presence of Vpu, we undertook triple label fluorescence
analysis (detecting Vpu, tetherin and the TGN or lysosomes) of
HeLa cells that had been incubated in the presence of
lysosomal inhibitors for 24 hours prior to processing for
fluorescent labelling. This demonstrated minimal accumulation
of tetherin in the TGN (Figure 6A), but significant accumulation
in lysosomes in both control cells and in expressing Vpu
(Figure 6B, quantified in Figure 6C). The fact that the majority
of endogenous tetherin is targeted for lysosomal degradation in
cells expressing Vpu was confirmed by immunoblot analysis of
lysates from cells that had been incubated in the presence of
lysosomal inhibitors (Figure 6D). In the absence of Vpu,
inhibition of lysosomal enzymes led to a small increase in
tetherin levels (left hand panel in Figure 6D; quantification in
Figure 6E), indicating tetherin is normally susceptible to
lysosomal degradation (this is consistent with the reported
short half-life of tetherin [40]). However, in cells expressing
Vpu, inhibition of lysosomal enzymes caused a much more
substantial (> two fold; Figure 6D and E) increase in tetherin
accumulation (compare central panel with left hand panel of
Figure 6D). In contrast, proteosomal inhibitors have a minimal
effect on endogenous tetherin levels whether or not cells
express Vpu (Figure 6D right hand panel, Figure 6E and data
not shown). Overall this confirms that Vpu directs the
lysosomal degradation of internalised tetherin.
Discussion
Thus i) we find no evidence for a stable interaction between
Vpu and endogenous tetherin at the cell surface, ii) the vast
majority of endogenous tetherin that is at the cell surface in
control cells is in lipid rafts, iii) internalised tetherin is present in
non-raft fractions, iv) expression of Vpu in cells expressing
endogenous tetherin leads to the loss of tetherin from lipid
rafts, v) internalised tetherin enters early endosomes, and late
endosomes, in both control cells and cells expressing Vpu, vi)
lysosomes are the primary site for degradation of endogenous
tetherin in cells expressing Vpu. It is therefore possible that an
interaction between Vpu and tetherin at the cell surface initially
removes tetherin from lipid rafts and that this is rapidly followed
by internalisation of the Vpu:tetherin complex (this rapid
removal of the complex would explain why we detect no cell
surface biotinylated tetherin co-immunoprecipitating with Vpu).
However, published data argue that expression of Vpu does
not affect the efficiency with which tetherin is internalised from
the cell surface [36,40]. An alternative, and possibly more
satisfactory, explanation is that, in both control cells and in cells
expressing Vpu, as tetherin is internalised it partitions from ‘raft’
to ‘non-raft’ regions of membrane. Soon after internalisation in
cells expressing Vpu, the tetherin encounters Vpu (this is
consistent with our observation that incubating biotinylated
cells at 37°C for 10 min, to allow internalisation of tetherin,
leads to a detectable interaction between Vpu and tetherin) and
this interaction modifies the intracellular trafficking route of
tetherin such that it is preferentially delivered to the lysosome
for degradation rather than being recycled to the cell surface.
This is consistent with the reported role of components of the
ESCRT (endosomal sorting complex required for transport)
machinery in Vpu-dependent degradation of tetherin [20,48].
The Vpu-mediated diversion from the recycling pathway would
appear to occur early in the endocytic pathway (as internalised
tetherin is detected in both early and late endosomes, whereas
Vpu is detected in early, but not late endosomes). The fact that
endogenous tetherin is susceptible to lysosomal degradation in
control cells (see Figure 6) indicates that it is inefficiently
recycled to the cell surface following internalisation in these
cells and is consistent with the previously published relatively
short half-life of tetherin [40]. Thus the encounter between
tetherin and Vpu early in the endocytic pathway simply seems
to tip the balance from a situation where some tetherin is
delivered to lysosomes for degradation but the majority is
recycled to the cell surface into one in which the lysosomal
pathway predominates. Thus, Vpu is not removing tetherin
from lipid rafts at the cell surface, rather, as tetherin is
internalised it exits lipid rafts (NB this is consistent with the
concept of lipid rafts as membrane microdomains that are
dynamic assemblies of lipids and proteins with constant
partitioning of components into and out of the rafts [12,13]) and
encounters Vpu; this encounter favours the lysosomal pathway
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Figure 5.  Immunolocalisation of internalized tetherin in the presence and absence of Vpu.  A-D. HeLa cells that had been
transiently transfected to express Vpu-GFP and which had been incubated in the presence of lysosomal enzyme inhibitors for 24
hours were incubated at 4°C for 60 min with a monoclonal antibody (HM1.24) that recognises the extracellular domain of tetherin.
Cells were then transferred to 37°C for various times and processed for immunofluorescence analysis using polyclonal antibodies to
markers of early (EEA-1, A, B) or late (LAMP-1, C, D) endosomes. Some of the internalised tetherin can be seen to colocalise with
both Vpu and EEA1 after 5 (A) or 10 (B) min at 37°C (see white arrows; bottom sets of panels represent magnifications of the boxed
regions from the corresponding images above and are 20µ2); however, there is greater evidence of colocalisation between
internalized tetherin and LAMP-1 at both time points (C and D). This is quantified by Pearson’s correlation coefficient (PCC) and
percentage pixel overlay (%O) in E. This co-localisation is greatest in cells that also express Vpu at both 5min (PCC P=0.027, %O
P=0.0015 n=3) and 10min (PCC P=0.0117, %O P=0.0034 n=3) antibody uptake. It is of note that there is limited evidence of any co-
localisation between Vpu and LAMP-1 (C and D). Bar = 10µ.
doi: 10.1371/journal.pone.0075680.g005
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Figure 6.  Lysosomal degradation of tetherin.  A.and B. Triple label fluorescence analysis (antibody detection of Vpu, tetherin
and TGN46, and LysoTracker detection of lysosomes) of HeLa cells that had been incubated in the presence of lysosomal inhibitors
for 24 hours prior to processing for immunofluorescence analysis. Cells expressing Vpu demonstrated significant accumulation of
tetherin in lysosomes (B), but not in the TGN (A). Bar = 10µ. C. Quantification of co-localisation between LysoTracker-594 and
tetherin, using both Pearson’s correlation coefficient and percentage pixel overlay. D. Immunoblot analysis, using an antibody to
endogenous tetherin, of lysates from control HeLa cells, or HeLa cells expressing Vpu-GFP (Vpu) that had been incubated in the
presence of lysosomal (24 hours) or proteosomal (12 hours) inhibitors (as indicated). The lower panels show immunoblots for
tubulin as loading controls. E. Graphical representation of quantification of the data presented in D, P=0.0002, n = 3.
doi: 10.1371/journal.pone.0075680.g006
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rather than the recycling pathway (see Figure 7). This
explanation is also consistent with the observations that it is not
necessary for Vpu to be present in lipid rafts for it to down-
regulate the level of tetherin expression [49]. Hence Vpu
appears to be playing roles in sequestration and degradation of
tetherin in both the endocytic and biosynthetic pathways [42].
Endogenous tetherin in HeLa cells is generally detected as a
diffuse smear of ~34kDa and above in immuoblot analysis of
cell lysates following treatment under reducing conditions and
separation by SDS-PAGE (e.g. see Figure 3). This smear
corresponds to heterogenous glycosylation of monomeric
tetherin. However, we note that the tetherin that co-
immunoprecipitates with Vpu is detected as a fairly sharp band
corresponding to an ~75kDa molecule following treatment
under reducing conditions and separation by SDS-PAGE (e.g.
see Figure 1C). We suggest that this molecule represents a
particular glycoform (hence the relative sharpness of the band)
of an SDS-resistant dimer (hence the increased molecular
mass) of tetherin.
Others have recently published that expression of Vpu has
no effect on the distribution of tetherin between raft and non-
raft membrane microdomains [50]. However, we note that
these authors used 0.5% Triton X-100 in their extraction
protocol (in contrast to the 1% Triton X-100 used here) prior to
sucrose density centrifugation. The experiments giving rise to
the data presented in Figure 3A were therefore repeated (at 24
and 48 hours post-transfection to express Vpu-GFP) using
0.5% Triton X-100 instead of 1% Triton X-100. Under these
conditions we also saw no effect of Vpu expression on the raft
vs. non-raft localisation of tetherin. This serves to highlight the
fact that aspects of the subtleties of lipid raft organisation can
be dissected by minor differences in detergent concentration in
differential extraction procedures.
Conclusions
We find i) no evidence for an interaction between Vpu and
endogenous tetherin at the cell surface, ii) the majority of
endogenous tetherin that is at the cell surface in control cells is
in lipid rafts, iii) internalised tetherin is present in non-raft
fractions, iv) expression of Vpu in cells expressing endogenous
tetherin leads to loss of tetherin from lipid rafts, v) internalised
tetherin enters early and late endosomes, in both control cells
and cells expressing Vpu, vi) lysosomes are the primary site for
degradation of endogenous tetherin in cells expressing Vpu.
Our studies underlie the importance of studying endogenous
tetherin and highlight the fact that recombinant tetherin can be
differentially localised between raft and non-raft fractions in
different cell types. We propose a model in which Vpu
intercepts newly internalised tetherin and diverts it for
lysosomal destruction rather than recycling to the cell surface.
Materials and Methods
Plasmids
The constructs encoding codon-optimized Vpu and codon-
optimized Vpu fused to enhanced GFP (eGFP) (VpuGFP) have
been reported previously [34]. C-terminally GFP tagged M2
(A/PR/8/34 strain) was produced by sub-cloning the M2 open
reading frame (amplified by RT-PCR from infected cells) into
the KpnI/AgeI sites of pEGFP-N1 (Clontech).
Antibodies
Rabbit polyclonal antiserum directed against the extracellular
portion of tetherin has been described previously [51] and was
obtained through the NIH AIDS Research and Reference
Reagent Program (catalog number 11721; https://
www.aidsreagent.org). This was used for immunoblots. A
mouse monoclonal antibody (HM1.24) to tetherin [1] was
provided by the Chugai Pharmaceutical Company. This was
used for immunofluorescence. Additional antibodies against
EEA1 (SantaCruz), TGN-46 (gift from Dr. S. Ponnambalam),
and LAMP-1 (gift from Dr. A. Toye) were also used for
Immunofluorescence.
Membrane preparations
Detergent resistant membranes were prepared and
separated on sucrose density gradients as previously
described [47]. 1ml fractions were taken from the sucrose
gradients, trichloroacetic acid precipitated, resuspended in
sample buffer and separated on a 15% SDS polyacrylamide
gel.
Biotinylation
Surface proteins were labelled on ice with 1mg/ml NHS-SS-
biotin in borate buffer (10mM orthoboric acid, 154mM NaCl,
7.2mM KCl, 7.2mM CaCl2) for 30 min. Excess biotin was
quenched with Glycine, washed with PBS and returned to ice.
Cells were either immediately lysed or put with pre-warmed
media at 37°C for 10 min and lysed TNE (1% Triton X-100, 150
mM NaCl, 10 mM EDTA) on ice. Lysates where then either
incubated immediately with streptavidin beads overnight or
separated on a sucrose density gradient. 1ml fractions were
pooled as indicated before incubation with streptavidin beads.
Proteins were eluted in 100µl of sample buffer.
Immunoprecipitation
Transfected cells where lysed and interacting proteins were
immunoprecipitated using the GFP-TRAP system according to
the manufacturer’s (Chromotek) protocol. For the double
immunoprecipitation procedure, proteins were eluted in 50µl of
elution buffer with 5% Sodium dodecylsulphate for 5 min at
95°C. After centrifugation the supernatant was removed and 1
ml elution buffer was added to dilute the SDS prior to
incubation with the streptavidin beads (as above).
Immunofluorescence
HeLa cells were cultured for immunofluorescence on glass
coverslips in DMEM (1% Penicillin-Streptomycin, 10% Foetal
bovine serum). After 24 hours, cells were transfected with 3µg
GFP-Vpu plasmid using Fugene HD (Promega). At 48hrs, cells
were treated with a Lysosomal inhibitor cocktail consisting of
40µM Leupeptin, 40µM Pepstatin, and 4µg/ml of e64D (all from
Sigma Aldrich). Immediately prior to fixation, LysoTracker-594
reagent (Molecular Probes) was added to the cell media at a
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Figure 7.  Cartoon representation of the effect of Vpu on tetherin trafficking following internalisation from the cell
surface.  The left hand side of the cartoon (green) shows what happens to cell surface tetherin in the absence of Vpu. It is
internalised and delivered to early endosomes. During this process it exits lipid rafts. The majority of tetherin molecules then end up
being recycled to the cell surface, probably via one or more intermediate compartment (as indicated by the thick arrows) whilst
some tetherin ends up in multivesicular bodies (MVBs)/late endosomes and is ultimately destined for lysosomal degradation. Thus
the fate of internalised tetherin is finely balanced between recycling to the cell surface and lysosomal degradation. The right hand
side of the cartoon (pink) shows what happens to cell surface tetherin in the presence of Vpu. Both are internalised and delivered to
early endosomes (with tetherin once again exiting lipid rafts along the way) where they associate with one another. This association
leads to a shift in the balance between recycling and lysosomal degradation for tetherin, with the majority of tetherin now destined
for delivery to MVBs/late endosomes and then to lysosomes (as indicated by the thick black arrows). NB this cartoon illustrates only
the effect of Vpu on the fate of internalised tetherin.
doi: 10.1371/journal.pone.0075680.g007
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concentration of 500µM, and incubated for 90min in order to
internalise the reagent. Cells were fixed at 72hrs with 3% PFA
in PBS, and permeabilised using 0.1% Triton X-100. Dual
immunolabelling of tetherin was performed by incubating with
the HM1.24 primary mouse monoclonal antibody and TGN-46
rabbit polyclonal antibody (see above) for 1 h, washing with
PBS, and incubating with Alexa Fluor 633- or 594-conjugated
secondary antibody for 0.5 h. Tetherin uptake experiments
were performed by incubating cells in PBS on ice for 20min,
followed by incubation on ice with HM1.24 antibody in DMEM
for 15min. Cells were then placed in DMEM at 37°C for 5min or
10min to allow antibody to be taken up, followed by washing
with PBS, fixation with 3% PFA in PBS and antibody labelling
with Lamp1 rabbit polyclonal or EEA1 goat polyclonal antibody
(see above). Fixed cells were imaged using a confocal laser-
scanning microscope (TCS-NT; Leica) equipped with a Kr/Ar
laser (488-, 594-, and 647-nm lines) attached to an upright
epifluorescence microscope (DMRBE; Leica). All images were
collected using a 63× NA 1.4 oil immersion objective and
processed with Leica software.
Inhibitor Assay
HeLa cells were either transfected with plasmid encoding
GFP-Vpu as above, or treated with a mock transfection. After
24 hours, cells were treated with Lysosomal Inhibitor Cocktail
(as above), Proteasomal Inhibitor (1µM MG132, Sigma
Aldrich), or left untreated. At 48hrs, cells were lysed in a buffer
consisting of 10 mM Tris-HCl, pH 7.4, and 10 mM EDTA with
protease inhibitors (Roche). Proteins were separated on 12 or
15% gels, transferred to PVDF and incubated with primary
antibody. Bound primary antibody was detected with HRP-
conjugated secondary antibody and chemiluminescence
(Roche).
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